Georgia Cancer Center

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell #RCC. @zklaassen_md @GACancerCenter & Vitaly Margulis, MD @UTSWMedCenter discuss the emerging role of Girentuximab PET-CT in #KidneyCancer. With >85% sensitivity/specificity (ZIRCON trial), it offers a “non-invasive, image-based biopsy” for select cases—useful in staging and guiding multimodal care. #WatchNow > bit.ly/46IFsof

The Gold Humanism Honor Society recognizes physicians who exemplify compassionate, patient-centered care and serve as role models for humanism in medicine. Priyanka Raval was selected for this recognition due to her outstanding dedication to both her patients and the community.

Moving beyond TURBT: Durable LG-IR #NMIBC control with primary chemoablation. @SPINCHS @AtlanticHealth and @zklaassen_md @GACancerCenter discuss long-term outcomes from the #ENVISION trial evaluating mitomycin (ZUSDURI™) for low-grade intermediate-risk nonmuscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/3X48RUj @UroGenPharma

Cohort P data from the BOND-003 study in BCG-unresponsive papillary #BladderCancer. @MarkTysonMD @MayoClinic joins @zklaassen_md @GACancerCenter in this discussion on UroToday. At median six-month follow-up, high-grade recurrence-free survival reached 95.7% at three months, 84.6% at six months, and 80.4% at nine months. #WatchNow on UroToday > bit.ly/4pTE4WH

⭐️ #ASH25 Insights w/@jorgecortesmd and @OncBrothers 🔑 #AML & #CML updates! ⭐️#PARADIGM ⭐️#KOMET-007 ⭐️#ASC4FIRST ⭐️#ASC2ESCALATE #MedEd #FOAMed #Leukemia #Hematology #MedTwitter #HemOnc @GACancerCenter #MedX @ASH_hematology Full Video Podcast 👇 oncupdates.com/video-podcasts…

My fiends at Humanitree House, my favorite restaurant in @CityofAugusta. Great food and even better service. I will miss you. @GACancerCenter @icmlf @BloodPortfolio @ASH_hematology

Devadatta Gosavi recently presented his work using TIRF microscopy & sensitized FRET to investigate the spatiotemporal coordination between talin-1 & kindlin-3 to elucidate the molecular mechanisms governing β₂-integrin activation & advance understanding of immune regulation.

Big day in the poster hall for our group! @DocHariKris and I shared 6 posters today spanning cardio-oncology + multi-omics in prostate cancer: connecting imaging, adiposity, immune remodeling, proteomics, and cardio–kidney–metabolic (CKM) risk. @TarekNahle @neerajaiims @GACancerCenter @anantm Poster lineup: •T1 MRI / radiomics: Skeletal muscle radiomic features on prostate T1-weighted MRI and association with major adverse cardiac events (MACE) @anantm •Obesity-associated epigenetic remodeling under androgen deprivation therapy (ADT) and implications for cardiometabolic risk @ImmunologyAU •CyTOF: CyTOF immune profiling: how obesity shapes biphasic immune remodeling (CD45+ circulating cells) during ADT @ImmunologyAU •Proteomics: Proteomic remodeling after ADT: how age modifies innate immune/complement–ECM pathways @mayo •CardioKidneyMetabolic Syndrome: CKM syndrome stages in prostate cancer and prognostic significance for CV morbidity/mortality •MRI T2 microenvironment: Periprostatic adipose microenvironment remodeling in aggressive prostate cancer (atlas-based geometric analysis) @anantm Really appreciated all the thoughtful questions and conversations: always energizing to share the work and hear new perspectives. If you’re here, come say hi! #ProstateCancer #CardioOncology #Radiomics #Epigenetics #CyTOF #Proteomics #CKM #CancerResearch #TranslationalScience #GU26 @ASCOPost @ASCO @OelsayedMD @EmoryAIHumanity . All abstracts out in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

🎧 In the latest episode of Cancer, Character, and Calling: The Oncologist’s Journey, Girindra Raval, MD, of @GACancerCenter is joined by @HosseinBorghaei of @FoxChaseCancer to discuss Dr Borghaei’s personal journey into medicine and oncology. #oncology #medwtitter 👉 Listen to the full episode here: hubs.li/Q044GJxn0

From aspiring physicist to cancer immunotherapy researcher, Bangxing Hong, PhD, is advancing innovative treatments for aggressive brain tumors at @GACancerCenter. jagwire.augusta.edu/an-unexpected-…

Real-world experience with the Expanded Access Program for 89Zr-girentuximab PET in small renal masses. R. Jonathan Henderson, MD @ArUrology, joins @zklaassen_md @GACancerCenter to share insights from implementing this technology in his high-volume Arkansas practice, noting that the #ZIRCON trial demonstrated approximately 90% sensitivity and specificity for identifying clear cell renal cell carcinoma. #WatchNow > bit.ly/4iqk0bW

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell #RCC. @zklaassen_md @GACancerCenter & Vitaly Margulis, MD @UTSWMedCenter discuss the emerging role of Girentuximab PET-CT in #KidneyCancer. With >85% sensitivity/specificity (ZIRCON trial), it offers a “non-invasive, image-based biopsy” for select cases—useful in staging and guiding multimodal care. #WatchNow > bit.ly/46IFsof

@pacelineride presented their check to @jorgecortesmd this morning! $366,217 raised during the PaceDay 2025 campaign, and it will all be going to research here at the GCC!

Fantastic work by our superstar 🌟@MCG_AUG med students 🎓📚 presenting two great posters at #Tandem26. @GACancerCenter @YennyMo64128602

We celebrated #WorldCancerDay with @AugustaJags & @AUG_University's Golf Team! Patients and Employees got to try their hand at the putting green, with some help with advice from the experts.

Randomized trial of the #NeuroSAFE technique in radical prostatectomy for erectile function. Eoin Dinneen & Ricardo Almeida-Magana join @zklaassen_md to discuss the NeuroSAFE PROOF trial—the first randomized study to show better erectile outcomes after radical prostatectomy. Using intraoperative frozen-section–guided nerve sparing, NeuroSAFE increased bilateral nerve preservation to 80% (vs 56%) and doubled the proportion of men with no/mild ED at 12 months (40% vs 22%), while also showing early continence benefits and strong recruitment of Black/Afro-Caribbean patients. #WatchNow > bit.ly/4k4IqbC @ucl @PeterMacCC @GACancerCenter

Join @GCC_Cortes and @gandhi_shipra at #SCHemBreast26 in #NorthAugusta on Jan 31. Register now: binaytara.org/projects/confe… #MedTwitter #MedX #MedEd #HemeOnc #hematology #BreastCancer @GACancerCenter @EmoryUniverstiy @WinshipatEmory

Join Dr. Betty Pace and Dr. Yenny Moreno Vanegas at #SCHemBreast26 in #NorthAugusta on Jan 31. Register now: binaytara.org/projects/confe… #MedTwitter #MedX #MedEd #HemeOnc #hematology #BreastCancer @GACancerCenter

Real-world experience with the Expanded Access Program for 89Zr-girentuximab PET in small renal masses. R. Jonathan Henderson, MD @ArUrology, joins @zklaassen_md @GACancerCenter to share insights from implementing this technology in his high-volume Arkansas practice, noting that the #ZIRCON trial demonstrated approximately 90% sensitivity and specificity for identifying clear cell renal cell carcinoma. #WatchNow > bit.ly/4iqk0bW

The @AmericanCancer said 70% of Americans are now alive 5 years after diagnosis. Be thankful. But still seek treatment as cancer becomes a chronic disease. You deserve to be comfortable, says Dr. Cortes of @GACancerCenter in my latest for After Treatment after-treatment.com/p/doctors-save…